Research Article

Alanine Aminotransferase and Body Composition in Obese Men and Women

Svein Ivar Bekkelund and Rolf Jorde

1Department of Clinical Medicine, UiT-The Arctic University of Norway, Tromsø, Norway
2Department of Neurology and Neurophysiology, University Hospital of North Norway, Tromsø, Norway
3Division of Internal Medicine, University Hospital of North Norway, N-9037 Tromsø, Norway

Correspondence should be addressed to Svein Ivar Bekkelund; svein.ivar.bekkelund@unn.no

Received 25 May 2019; Accepted 30 July 2019; Published 26 August 2019

Academic Editor: Małgorzata Knaś

Copyright © 2019 Svein Ivar Bekkelund and Rolf Jorde. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

There is a known relationship between serum alanine aminotransferase (ALT) and obesity in humans, but the mechanism(s) are not clarified. This study investigated the associations between serum ALT and body composition in an overweight and obese population. The results are based on data from a previous randomized controlled trial treating obesity with vitamin D3. A sample of 448 overweight and obese individuals underwent dual-energy X-ray absorptiometry (DEXA) and measured serum ALT along with supplementary blood samples at study baseline. Body fat mass and lean mass indexes were calculated by dividing total body fat/lean weight (kg) by body height squared (kg/m2). ALT correlated with body mass index (BMI) in men but not women (r = 0.33, P < 0.0001 vs. r = 0.06, P = 0.29). In men, serum ALT correlated positively with fat mass index (r = 0.23, P = 0.004) and lean mass index (r = 0.32, P < 0.0001). In women, ALT correlated with lean mass index (r = 0.13, P = 0.031) but not fat mass index (r = 0.003, P = 0.96). In a multivariate model adjusted for age and fat mass index, a 1-unit increase in lean mass index associated with a 0.37 U/L higher ALT in the male subgroup (95% CI 0.024 to 0.040, P < 0.0001). In conclusion, serum ALT was associated with body fat mass index in men and with lean mass index in men and women in an overweight and obese population. The findings also demonstrate a gender difference in the role of fat.

1. Introduction

Alanine transaminase (ALT) is associated with obesity [1, 2], cardiovascular disease (CVD), and CVD-related mortality [3–5]. Clinical and population studies have related ALT with insulin resistance, metabolic syndrome, and type 2 diabetes [6–8]. Obesity is reported to be a major risk factor to develop nonalcoholic fatty liver disease (NAFLD), a common liver disease defined as ≥5% fat liver [9], and an important mechanism behind the relationship between ALT and risk of CVD [10, 11]. Hepatic accumulation of lipids occurs initially while inflammation and oxidative stress in response to increased lipid activity are further reaction characteristic for the disease [12, 13].

A Korean population study showed a higher risk of elevated ALT by increasing degree of BMI [14]. Odds ratio for elevated ALT in obese subjects was 5.0 in men and 3.9 in women [14]. In studies from the United States confirming a positive relationship between ALT and BMI, the strongest association was found for waist-to-hip ratio [15] and trunk fat using dual-energy X-ray absorptiometry (DEXA) to measure body composition, indicating central adiposity to be an important obesity-related determinant of elevated ALT [16]. ALT was also associated with trunk lean mass in both sexes [16].

Little is known about the muscular role of ALT in general, and obesity in particular, but the parallel increase and the following recovery of ALT released to the circulation in response to muscle injury, seizure, and inflammation may reflect some underlying mechanisms [17, 18]. There is emerging evidence that loss of muscle mass (sarcopenia) plays a role in the complex pathophysiology of NAFLD [19]. One link between them is insulin resistance, which is associated with muscle loss [20]. Furthermore, in a
2. Material and Methods

2.1. Study Participants. Using data from a randomized controlled trial (RCT) treating obesity with vitamin D3 [22], the present study was designed with the following criteria: males and females 21-70 years of age with BMI between 28.0 and 47.0 kg/m² were accepted for inclusion. Diabetes, history of heart infarction, angina pectoris and stroke, weight loss > 10 kg last six months, use of antidepressants and drugs with weight-reducing properties, participation in weight loss programs, pregnant and lactating women, women with pregnancy plans next 12 months, sants and drugs with weight-reducing properties, participation in alcohol advertising or from the medical outpatient clinic at the University Hospital of North Norway. Written consent was obtained from all, and the Norwegian Committee for Medical and Health Research Ethics (REC) approved the study. The study was conducted in accordance with the Helsinki Declaration.

2.2. Measurements. Only baseline data were used. Standardized measurements of height and weight were performed with light clothing without shoes, and body mass index (BMI) was calculated as weight (kg) divided by height squared (m²). Body composition measurements with DEXA (GE Lunar Prodigy, LUNAR Corporation, Madison, WI, USA) were performed, and body fat index was calculated by dividing total body fat weight (kg) by body height squared (m²). The same was done for lean mass. Physical activity, a potential confounder, was calculated by the short version (7 days) of the International Physical Activity Questionnaire (IPAC) [23]. Vigorous, moderate, and walking activities are transformed to units of metabolic equivalents (MET)-min/week, where METs are multiples of the resting metabolic rates.

Serum ALT was analyzed consecutively within 6 hours after the phlebotomies in an automated clinical chemistry analyzer (Modular P, Roche) by photometry, using an enzymatic method (CK-NAC, Roche Diagnostics, Mannheim, Germany). Reference limits for serum ALT were 10-70 U/L (men) and 10-45 U/L (women). The lower detection limit of ALT assay was 5.0 U/L. The analytical variation (Vka) of ALT is 4.9%. The standard cut-off limits for ALT and AST used in the hospital are developed by the Nordic Reference Interval Project (NORIP) [24]. AST/ALT ≥ 2 and ≥3 were calculated to detect participants at risk of alcoholic liver disease [25]. Gamma-glutamyl transpeptidase (GGT) was measured with references 10-80 U/L (men 18-39 years), 15-115 U/L (men ≥ 40 years), 10-45 U/L (women 18-39 years), and 10-75 U/L (women ≥ 40 years) with 3.2% Vka. Nonfasting S-glucose and glycosylated hemoglobin (HbA1c) in EDTA whole blood based on an immune turbidometric assay (UNIMATES, F. Hoffmann-La Roche AG) were obtained. The Hba1c% was calculated from the HbA1c/Hb ratio. Serum total cholesterol was analyzed by an enzymatic colorimetric method using a commercially available kit (CHOD-PAP, Boehringer-Mannheim, Mannheim, Germany). All analyses were done at the Department of Clinical Biochemistry, University Hospital of North Norway.

2.3. Statistical Analysis. The statistical analysis was performed by SPSS software version 25 (SPSS INC., Chicago, Illinois, USA). Distributions of the data were reviewed by visual inspection of histograms and by calculation of kurtosis and skewness. The histograms showed right-sided skewness in all endpoint variables. Serum ALT (skewness 2.7, kurtosis 4.0) and serum AST (skewness 4.2, kurtosis 37.3) confirmed a non-Gaussian distribution of the data. Log-transformed data were normal-distributed and therefore used in the analyses. The analyses were performed sex-stratified since levels of ALT and components of body composition are different in men and women. Descriptive data are presented as mean ± standard deviations (SD) or numbers and frequencies. Two-sided Student’s t-test was used to calculate differences between means and ANOVA used to compare body composition with quartiles of ALT (analyses of trends). The χ² test was used to compare frequencies of data within groups (dichotomous data). By multiple regression analysis, possible confounders were tested and adjusted for with ALT as dependent variables, and variables that significantly correlated with ALT were included in the regression model as independent variables. Regression coefficients (β) with 95% confidence interval (CI) were calculated. The level of significance was set at ≥5%.

3. Results

Clinical variables of the study population are listed in Table 1. A majority of the participants were obese (BMI ≥ 30 kg/m²), while about 10% of both sexes were overweight (25 ≥ BMI < 30 kg/m²) (Table 1). ALT was associated with BMI in men but not in women (Table 2), and BMI was significantly associated with ALT quartiles in men (Table 3). In contrast to women, ALT correlated positively with fat mass index in men and with lean mass indexes in both sexes (Table 2, Figures 1–4). ALT was significantly correlated with serum glucose, HbA1c and cholesterol in women but not in men (Table 2). The highest ALT value was 120 U/L (woman) and the highest AST was 137 U/L.
Table 1: Clinical characteristics of the subjects. Numbers (%) or mean (SD) is presented.

| Variables                        | Total group (n = 448) | Men (n = 157) | Women (n = 291) | P    |
|----------------------------------|-----------------------|---------------|-----------------|------|
| Age (years)                     |                       |               |                 |      |
|                                 | 47.5 (11.4)           | 47.8 (10.8)   | 47.4 (11.8)     | 0.15 |
| Use of antihypertensive drugs    | 93 (20.8)             | 33 (21.0)     | 60 (20.6)       | 1.0  |
| Statin use                       | 43 (9.6)              | 12 (7.6)      | 31 (10.7)       | 1.0  |
| NSAID                            | 74 (16.5)             | 27 (17.2)     | 47 (16.2)       | 1.0  |
| H2-blocking drugs                | 14 (3.1)              | 3 (1.9)       | 11 (3.8)        | 1.0  |
| Antidepressants                  | 25 (5.6)              | 10 (6.4)      | 15 (5.2)        | 0.52 |
| Height (cm)                      | 169.3 (8.9)           | 178.3 (6.1)   | 164.5 (6.0)     | 0.76 |
| Weight (kg)                      | 99.3 (14.2)           | 109.2 (11.2)  | 94.0 (11.7)     | 0.020|
| BMI (kg/m²)                      | 34.6 (3.9)            | 34.3 (3.6)    | 34.7 (4.1)      | 0.15 |
| Obesity (BMI ≥ 30 kg/m²)         | 406 (90.6)            | 141 (89.8)    | 265 (91.1)      | 0.73 |
| Overweight (25 ≥ BMI < 30 kg/m²) | 42 (9.4)              | 16 (10.2)     | 26 (8.9)        | 1.0  |
| Fat mass (kg)                    | 40.6 (8.3)            | 36.7 (8.4)    | 42.6 (7.6)      | 0.018|
| Lean mass (kg)                   | 54.2 (11.7)           | 67.5 (7.4)    | 47.1 (5.9)      | 0.027|
| Fat mass index (kg/m²)           | 14.3 (3.4)            | 11.5 (2.6)    | 15.8 (2.8)      | <0.0001|
| Lean mass index (kg/m²)          | 18.7 (2.6)            | 21.2 (1.9)    | 17.4 (1.9)      | <0.0001|
| ALT (U/L)*                       | 31.2 (17.5)           | 38.5 (15.9)   | 27.3 (17.1)     | <0.0001|
| High ALT**                       | 38 (8.5)              | 4 (2.5)       | 34 (11.7)       | 0.001|
| AST (U/L)*                       | 25.7 (10.0)           | 29.0 (8.7)    | 24.0 (10.3)     | 0.72 |
| High AST**                       | 37 (8.3)              | 12 (7.6)      | 25 (8.6)        | 0.86 |
| GGT (U/L)                        | 32.0 (38.8)           | 37.2 (39.2)   | 27.4 (37.9)     | <0.0001|
| Creatine kinase (U/L)*           | 121.6 (120.3)         | 178.5 (180.7) | 91.0 (46.3)     | <0.0001|
| S-glucose (mmol/L)               | 5.35 (0.64)           | 5.47 (0.59)   | 5.27 (0.64)     | 0.92 |
| S-HbA1C (%)                      | 5.66 (0.38)           | 5.67 (0.42)   | 5.65 (0.36)     | 0.14 |
| Hs-CRP (mg/dL)*                  | 4.08 (4.87)           | 3.30 (4.71)   | 4.45 (4.82)     | 0.08 |
| S-total cholesterol (mmol/L)     | 5.37 (1.00)           | 5.40 (0.89)   | 5.36 (1.06)     | 0.022|
| Physical activity score (MET-min/week)* | 3207.0 (3836.0) | 3046.7 (4273.2) | 3297.8 (3587.4) | <0.0001|

BMI: body mass index; ALT: alanine transaminase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transpeptidase; Hs-CRP: high sensitive C-reactive protein; MET: metabolic equivalent; NSAID: nonsteroid antillogistic drugs. *Analyzed log-transformed. **Above reference limit.

Table 2: Correlations between ALT*, body composition, and potential confounders.

|                      | ALT (U/L) |                      |                      |      |
|----------------------|-----------|-----------------------|-----------------------|------|
|                      | Men (n = 157) | P               | Women (n = 291) | P    |
| Age (years)          | -0.19     | 0.017                 | 0.23                  |      |
| BMI (kg/m²)          | 0.33      | <0.0001               | 0.006                 | 0.29 |
| Fat mass index (kg/m²)| 0.23    | 0.004                 | 0.003                 | 0.96 |
| Lean mass index (kg/m²)| 0.32   | <0.0001               | 0.13                  | 0.031|
| Creatine kinase (U/L)* | 0.15   | 0.07                  | 0.06                  | 0.35 |
| S-glucose (mmol/L)   | 0.09      | 0.27                  | 0.23                  | <0.0001|
| S-HbA1C (%)          | 0.11      | 0.18                  | 0.19                  | 0.001|
| Hs-CRP (mg/dL)*      | 0.06      | 0.44                  | -0.01                 | 0.84 |
| S-total cholesterol (mmol/L) | 0.02 | 0.86                  | 0.16                  | 0.005|
| Physical activity score (MET-min/week)* | -0.09 | 0.31                  | -0.02                 | 0.80 |

BMI: body mass index; ALT: alanine transaminase; Hs-CRP: high sensitive C-reactive protein; MET: metabolic equivalent. *Analyzed log-transformed.
Nine participants (3 men and 6 women) had AST/ALT index ≥ 2 and 2 women had AST/ALT index ≥ 3.

Fat mass and lean mass indexes increased significantly with increasing quartiles of serum ALT in men in a trend analysis using ANOVA (Table 4). In contrast, lean mass but not fat mass indexes increased significantly from quartiles 1 to 4 of serum ALT in women (Table 3). Lean mass index was inversely and independently associated with serum ALT when adjusted for covariates in men (Table 4). Furthermore, a 1-unit increase in lean mass was associated with 0.37 U/L higher serum ALT when adjusted for age and fat mass index (Table 4). This association was independent and significant also when replacing body composition variables with BMI (data not shown).

4. Discussion

ALT was log-linearly and positively associated with fat mass index and lean mass index in men and with lean mass index in women in an obese cohort. After adjusting for obesity-related variables, body lean mass index remained independently associated with ALT in the male subgroup. ALT may hypothetically play a favourable role in the adipose process, but the fat mass component of body composition may act differently in women.

Although ALT is mainly located in the liver, alanine synthesis also occurs in muscle tissue [26, 27]. A parallel increase and recovery after muscular strain in both ALT and in the energy reactive muscle enzyme creatine kinase

---

**Table 3: Fat mass index, lean mass index, and confounders in quartiles of serum ALT.**

| ALT* quartiles | Q1      | Q2      | Q3      | Q4      | P for trend |
|---------------|---------|---------|---------|---------|------------|
| Q-intervals (U/L) (men) | ≤1.42   | 1.43-1.54 | 1.55-1.66 | ≥1.67   |            |
| N = 157       | 37      | 40      | 38      | 42      |            |
| Age (years)   | 51.1 (11.9) | 48.8 (11.8) | 45.6 (9.6) | 45.9 (10.0) | 0.09       |
| BMI (kg/m²)   | 32.7 (3.3)  | 33.8 (3.5)  | 34.7 (3.0)  | 36.0 (3.5)  | <0.0001    |
| Fat mass index (kg/m²) | 10.4 (2.2) | 11.7 (2.6)  | 11.6 (2.6)  | 12.3 (2.4)  | 0.008      |
| Lean mass index (kg/m²) | 20.7 (1.7) | 20.7 (1.8)  | 21.5 (1.5)  | 22.2 (2.0)  | <0.0001    |
| Q-intervals (U/L) (women) | ≤1.22   | 1.23-1.33 | 1.34-1.48 | ≥1.49   |            |
| N = 291       | 69      | 72      | 71      | 79      |            |
| Age (years)   | 42.4 (12.1) | 45.7 (12.0) | 50.6 (12.4) | 51.0 (9.8) | <0.0001    |
| BMI (kg/m²)   | 33.9 (3.8)  | 34.6 (3.9)  | 35.7 (4.3)  | 34.7 (4.2)  | 0.62       |
| Fat mass index (kg/m²) | 15.5 (2.7) | 15.5 (2.9)  | 16.6 (2.9)  | 15.5 (2.7)  | 0.10       |
| Lean mass index (kg/m²) | 16.9 (1.7) | 17.4 (1.6)  | 17.5 (2.1)  | 17.7 (1.9)  | 0.078      |
| S-glucose (mmol/L) | 5.06 (0.60) | 5.19 (0.55) | 5.45 (0.71) | 5.37 (0.60) | 0.001      |
| S-HbA1C (%)    | 5.54 (0.34) | 5.61 (0.36) | 5.76 (0.36) | 5.67 (0.34) | 0.003      |
| S-total-cholesterol (mmol/L) | 5.02 (0.94) | 5.18 (1.11) | 5.63 (1.04) | 5.54 (1.03) | 0.001      |

ALT: alanine transaminase; Q1: first quartile; Q2: second quartile; Q3: third quartile; Q4: fourth quartile. *Analyzed log-transformed.

Figure 1: Correlation between alanine aminotransferase (ALT) and fat mass in 157 obese men (r = 0.23, P = 0.004).
(CK) are reported [18]. In patients with rhabdomyolyses (CK ≥ 1000 U/L), 75% had abnormal ALT, which confirms its muscular involvement [28]. In contrast to ALT, CK was not associated with muscle mass in obese subjects measured at rest indicating different muscular relationships between them [29]. Whether ALT plays a positive or negative role, or both, in the CVD processes is discussed in the literature. Sarcopenia (age-related loss of muscle mass and strength) is an area of research where the ALT-muscular relationship has been questioned. Both adiposity and sarcopenia share in common an increased risk of NAFLD, and both have been associated with ALT and insulin resistance [14, 21, 30]. Furthermore, increased ALT may predict reduced insulin sensitivity and diabetes [6, 7]. The mechanisms are complex and incompletely understood, but the relationship between ALT and muscle mass as well as insulin resistance may be mediated by inflammation. ALT was associated with low-graded inflammation (CRP) in 1483 middle-aged Japanese men, and proinflammatory cytokines may exert a negative (catabolic) muscular effect [31, 32]. Additionally, insulin resistance in skeletal muscle may be produced by inflammatory activity such as tumor necrosis factor alpha and complement 3 [33, 34]. It is previously known that obesity-related inflammation stimulate progression of NAFLD and development of insulin resistance [12, 13]. Lack of relationship between ALT and CRP in the present study does not exclude the influence of inflammatory metabolites, however.

The Korean sarcopenia obesity study reported recently a 5.2-time increased risk of NAFLD in the sarcopen obese group compared to nonobese [30]. An inverse correlation between ALT and skeletal muscle mass index as well as total body fat and additionally negative correlations with CRP,
components of metabolic syndrome, and LDL-cholesterol were reported [30]. Moreover, ALT was inversely associated with sarcopenia, CVD, and overall mortality in 765 elderly subjects analyzed in prospective population-based data [35]. ALT correlated with appendicular lean mass, trunk lean mass, and total lean mass but not fat mass in a group of 174 healthy young athletic women [36]. A US population-based study measuring body mass with DEXA showed an association between lower ALT and mortality risk [37]. Lower values of appendicular lean mass were found in the three lowest ALT centiles when adjusted for total body fat mass, which could possibly explain the lower mortality rate in those with low ALT values [37]. In line with this, ALT was inversely and linearly associated with CVD risk in a 10.5-year follow-up study that included 6899 participants and 729 CVD events [38]. We did not measure partial body composition such as appendicular lean mass, neither was muscular power examined. Highly significant associations between ALT and total body lean mass in the present study in otherwise healthy obese individuals make that explanation less likely. ALT, by its muscular connection, may hypothetically play a beneficial role in the adipose process. The interrelationships between ALT, NAFLD, lean mass, and inflammation should be targeted in future studies.

ALT is connected with adiposity and CVD risk factors [39]. A positive association between ALT and trunk fat independent of trunk and extremity lean mass was found in one study [16], while central adiposity along with generalized adiposity is reported by others [5]. Furthermore, ALT was not elevated in otherwise healthy obese people in a clinical study with limited number of participants contrasting our results [40]. This corresponds approximately with the relatively small subgroup with elevated ALT frequency (about 8%) found in the present study. Overall, relationships between ALT and CVD risk are complex [41, 42]. Additionally, how lean mass and fat mass act in the atherosclerotic process is not clear. Lean mass was independently associated with carotid media thickness in 421 obese subjects [43] and was associated with carotid lumen diameter in another study [44]. On the other hand, lean mass predicted a better cardiac function in a 10-year follow-up study of obese subjects indicating a protective CVD effect [45].

As found in the present study, ALT is reported to be higher in males than females [46, 47]. Whether this is due to different fat vs. lean mass contribution, the effect of sex hormones or other mechanisms is not known. The positive relationship between ALT and the muscular component relative to fat in the female group of the present obese body composition sample illustrates the complexity of body composition and its connection with ALT. Whether ALT may play a beneficial role in the adipose female process is an open question. Thus, ALT predicted coronary heart disease in men but not in women in a European-American

Table 4: Associations between ALT* (dependent variable) and independent variables in overweight and obese men and women.

|            | ALT (U/L) as dependent variable | 95% CI | P         |
|------------|--------------------------------|--------|-----------|
| Men (n = 157) |                               |        |           |
| Age (years) | 0.12                           | 0.001 to 0.004 | 0.008    |
| Fat mass index (kg/m²) | 0.06                           | -0.10 to 0.002 | 0.18     |
| Lean mass index (kg/m²) | 0.37                           | 0.024 to 0.040 | <0.0001  |
| Adjusted R² | 0.16                           |        |           |
| Women (n = 291) |                               |        |           |
| Age (years) | 0.15                           | 0.000 to 0.005 | 0.034    |
| Lean mass index (kg/m²) | 0.11                           | 0.000 to 0.027 | 0.051    |
| S-glucose (mmol/L) | 0.17                           | 0.014 to 0.113 | 0.01     |
| S-HbA1c (%) | 0.04                           | -0.063 to 0.120 | 0.54     |
| S-total-cholesterol (mmol/L) | 0.06                           | -0.130 to 0.40 | 0.31     |
| Adjusted R² | 0.09                           | 0.000 to 0.005 | 0.034    |

ALT: alanine transaminase. *Analyzed log-transformed. **Values are regression coefficients (95% CI) expressed in ALT U/L for a 1-unit change in independent variables.

Figure 4: Correlation between alanine aminotransferase (ALT) and lean mass in 291 obese women (r = 0.13, P = 0.031).
population-based study [48]. Further, a link between ALT and muscular glucose uptake was found in women only, which may hypothetically explain why ALT appears to play a different role as a CVD risk marker in men and women [49]. In parallel, ALT correlated with metabolic variables (glucose, HbA1c, and cholesterol) in women but not in men in the present study. In a large Italian study, ALT associated positively with BMI, glucose, cholesterol, and triglycerides and increased with younger age groups (until third decade in males and fifth decade in females) but decreased in older age groups [50]. Consequently, gender should be taken into account when planning clinical ALT studies.

4.1. Strengths and Shortcomings. Although the risk of statistical type 2 error is higher in secondary research studies due to uncertain sample size and invalid selection criteria, the larger female subgroup provides evidence to support the findings of gender differences in this study. BMI do not distinguish between fat and muscle content, nor does it reflect body fat distribution. These characteristics may impair the validity of BMI as an obesity marker and argue for the use of DEXA in such studies [51, 52]. Similarly, people with sarcopenic phenotype, i.e., those with increased adipose tissue and reduced muscle mass, may be overlooked by BMI [52]. Physical activity score did not alter the results here but is a potential confounder to consider in such studies [18, 53]. A drawback to the study is lack of information about alcohol consumption since ALT and AST are not sensitive alcohol markers [54].

5. Conclusion

ALT was positively associated with body lean mass in men and women but associated with fat mass only in men in this obese population. These findings suggest that the ALT-obesity relationship may partly be explained by different gender biology. Whether lean mass is more important than fat mass to explain how ALT relates to obesity needs to be confirmed and further investigated.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Acknowledgments

This study was supported by grants from North Norway Health Authority. The publication charges for this article have been funded by a grant from the publication fund of UiT, The Arctic University of Norway.

References

[1] L. A. Adams, M. W. Knuiman, M. L. Divitini, and J. K. Olynyk, "Body mass index is a stronger predictor of alanine aminotransaminase levels than alcohol consumption," Journal of Gastroenterology and Hepatology, vol. 23, 7, Part 1, pp. 1089–1093, 2008.

[2] S. Stranges, J. M. Dorn, P. Muti et al., "Body fat distribution, relative weight, and liver enzyme levels: a population-based study," Hepatology, vol. 39, no. 3, pp. 754–763, 2004.

[3] M. Yokoyama, T. Watanabe, Y. Otaki et al., "Association of the aspartate aminotransferase to alanine aminotransferase ratio with BNP level and cardiovascular mortality in the general population: the Yamagata study 10-year follow-up," Disease Markers, vol. 2016, Article ID 4857917, 9 pages, 2016.

[4] R. K. Schindhelm, J. M. Dekker, G. Nijpels et al., "Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn study," Atherosclerosis, vol. 191, no. 2, pp. 391–396, 2007.

[5] M. Klein, L. Iazzetti, P. Speiser et al., "Alanine transferase: an independent indicator of adiposity related comorbidity risk in youth," Journal of Diabetes, vol. 7, no. 5, pp. 649–656, 2015.

[6] B. Vozarova, N. Stefan, R. S. Lindsay et al., "High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes," Diabetes, vol. 51, no. 6, pp. 1889–1895, 2002.

[7] A. J. G. Hanley, L. E. Wagenknecht, A. Festa, R. B. D’Agostino, and S. M. Haffner, "Alanine aminotransferase and directly measured insulin sensitivity in a multiethnic cohort: the insulin resistance atherosclerosis study," Diabetes Care, vol. 30, no. 7, pp. 1819–1827, 2007.

[8] M. Jacobs, M. M. van Greevenbroek, C. J. H. van der Kallen et al., “The association between the metabolic syndrome and alanine amino transferase is mediated by insulin resistance via related metabolic intermediates (the Cohort on Diabetes and Atherosclerosis Maastricht [CODAM] study),” Metabolism, vol. 60, no. 7, pp. 969–975, 2011.

[9] European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO), “EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease,” Journal of Hepatology, vol. 64, no. 6, pp. 1388–1402, 2016.

[10] D. E. Kleiner, E. M. Brunt, M. van Natta et al., “Design and validation of a histological scoring system for nonalcoholic fatty liver disease,” Hepatology, vol. 41, no. 6, pp. 1313–1321, 2005.

[11] C. Matteoni, Z. Younossi, T. Gramlich, N. Boparai, Y. Liu, and A. Mccullough, “Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity,” Gastroenterology, vol. 116, no. 6, pp. 1413–1419, 1999.

[12] Z. P. Fricker, A. Pedley, J. M. Massaro et al., “Liver fat is associated with markers of inflammation and oxidative stress in analysis of data from the Framingham heart study,” Clinical Gastroenterology and Hepatology, vol. 17, no. 6, pp. 1157–1164.e4, 2019.

[13] D. B. Ballak, P. van Essen, J. A. van Diepen et al., "MAP3K8 (TPL2/COT) affects obesity-induced adipose tissue inflammation without systemic effects in humans and in mice," PLoS One, vol. 9, no. 2, article e89615, 2014.

[14] J. Kim and I. Jo, “Relationship between body mass index and alanine aminotransferase concentration in non-diabetic
Age-related decrease in skeletal muscle mass is an independent risk factor for incident nonalcoholic fatty liver disease: a 10-year retrospective cohort study, *Gut and Liver*, vol. 13, no. 1, pp. 67–76, 2019.

M. Sneve, Y. Figenschau, and R. Jorde, "Supplementation with cholecalciferol does not result in weight reduction in overweight and obese subjects," *European Journal of Endocrinology*, vol. 159, no. 6, pp. 675–684, 2008.

C. L. Craig, A. L. Marshall, M. SJÖSTRÖM et al., "International physical activity questionnaire: 12-country reliability and validity," *Medicine and Science in Sports and Exercise*, vol. 35, no. 8, pp. 1381–1395, 2003.

P. Rustad, P. Felding, and A. Lahti, "Proposal for guidelines to establish common biological reference intervals in large geographical areas for biochemical quantities measured frequently in serum and plasma," *Clinical Chemistry and Laboratory Medicine (CCLM)*, vol. 42, no. 7, pp. 783–791, 2004.

D. Sorbi, J. Boynton, and K. D. Lindor, "The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease," *The American Journal of Gastroenterology*, vol. 94, no. 4, pp. 1018–1022, 1999.

A. J. Garber, I. E. Karl, and D. M. Kipnis, "Alanine and glutamine synthesis and release from skeletal muscle. II. The precursor role of amino acids in alanine and glutamine synthesis," *The Journal of Biological Chemistry*, vol. 251, no. 3, pp. 836–843, 1976.

A. J. Garber, I. E. Karl, and D. M. Kipnis, "Alanine and glutamine synthesis and release from skeletal muscle. I. Glycolysis and amino acid release," *The Journal of Biological Chemistry*, vol. 251, pp. 826–835, 1976.

K. Weibrecht, M. Dayno, C. Darling, and S. B. Bird, "Liver aminotransferases are elevated with rhabdomyolysis in the absence of significant liver injury," *Journal of Medical Toxicology*, vol. 6, no. 3, pp. 294–300, 2010.

S. I. Bekkelund and R. Jorde, "Creatine kinase in relation to body fat in a Caucasian overweight and obese population," *Scandinavian Journal of Clinical and Laboratory Investigation*, vol. 78, no. 1–2, pp. 43–48, 2018.

H. C. Hong, S. Y. Hwang, H. Y. Choi et al., "Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean sarcopenic obesity study," *Hepatology*, vol. 59, no. 5, pp. 1772–1778, 2014.

I. Beyer, T. Mets, and I. Bautmans, "Chronic low-grade inflammation and age-related sarcopenia," *Current Opinion in Clinical Nutrition and Metabolic Care*, vol. 15, no. 1, pp. 1–22, 2012.

J. Yamada, H. Tomiyama, M. Yambe et al., "Elevated serum levels of alanine aminotransferase and gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the metabolic syndrome," *Atherosclerosis*, vol. 189, no. 1, pp. 198–205, 2006.

C. de Alvaro, T. Teruel, R. Hernandez, and M. Lorenzo, "Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner," *The Journal of Biological Chemistry*, vol. 279, no. 17, pp. 17070–17078, 2004.

M. M. J. van Greevenbroek, M. Jacobs, C. J. H. van der Kallen et al., "The cross-sectional association between insulin resistance and circulating complement C3 is partly explained by plasma alanine aminotransferase, independent of central obesity and general inflammation (the CODAM study)," *European Journal of Clinical Investigation*, vol. 41, no. 4, pp. 372–379, 2011.

U. Vespasiani-Gentilucci, A. de Vincentis, L. Ferrucci, S. Bandinelli, R. Antonelli Incalzi, and A. Picardi, "Low alanine aminotransferase levels in the elderly population: frailty, disability, sarcopenia, and reduced survival," *The Journals of Gerontology: Series A*, vol. 73, no. 7, pp. 925–930, 2018.

S. Minato, K. Kitaoka, M. Takeuchi et al., "Appendicular muscle mass and fasting triglycerides predict serum liver aminotransferases in young female collegiate athletes," *BMJ Open Diabetes Research & Care*, vol. 6, no. 1, article e000498, 2018.

C. E. Ruhl and J. E. Everhart, "The association of low serum alanine aminotransferase activity with mortality in the US population," *American Journal of Epidemiology*, vol. 178, no. 12, pp. 1702–1711, 2013.

S. K. Kunutsor, S. J. L. Bakker, J. E. Kootstra-Ros, H. Blokzijl, R. T. Gansevoort, and R. P. F. Dullaart, "Inverse linear associations between liver aminotransferases and incident cardiovascular disease risk: the PREVEND study," *Atherosclerosis*, vol. 243, no. 1, pp. 138–147, 2015.

J. M. Clark, F. L. Brancati, and A. M. Diehl, "The prevalence and etiology of elevated aminotransferase levels in the United States," *The American Journal of Gastroenterology*, vol. 98, no. 5, pp. 960–967, 2003.

G. Iacobellis, A. Moschetta, M. C. Ribaudo, A. Zappaterreno, C. V. Iannucci, and F. Leonetti, "Normal serum alanine aminotransferase activity in uncomplicated obesity," *World Journal of Gastroenterology*, vol. 11, no. 38, pp. 6018–6021, 2005.

S. K. Kunutsor, T. A. Apekey, and H. Khan, "Liver enzymes and risk of cardiovascular disease in the general population: a meta-analysis of prospective cohort studies," *Atherosclerosis*, vol. 236, no. 1, pp. 7–17, 2014.

M. Afarideh, Z. Aryan, A. Ghajari et al., "Complex association of serum alanine aminotransferase with the risk of future cardiovascular disease in type 2 diabetes," *Atherosclerosis*, vol. 254, pp. 42–51, 2016.
[43] M. Moreno, J. Puig, J. M. Moreno-Navarrete et al., “Lean mass, and not fat mass, is an independent determinant of carotid intima media thickness in obese subjects,” *Atherosclerosis*, vol. 243, no. 2, pp. 493–498, 2015.

[44] D. Kardassis, M. Schönander, L. Sjöström, and K. Karason, “Carotid artery remodelling in relation to body fat distribution, inflammation and sustained weight loss in obesity,” *Journal of Internal Medicine*, vol. 275, no. 5, pp. 534–543, 2014.

[45] D. Kardassis, O. Bech-Hanssen, M. Schonander, L. Sjostrom, M. Petzold, and K. Karason, “Impact of body composition, fat distribution and sustained weight loss on cardiac function in obesity,” *International Journal of Cardiology*, vol. 159, no. 2, pp. 128–133, 2012.

[46] D. Prati, E. Taioli, A. Zanella et al., “Updated definitions of healthy ranges for serum alanine aminotransferase levels,” *Annals of Internal Medicine*, vol. 137, no. 1, pp. 1–10, 2002.

[47] H. Poustchi, J. George, S. Esmaili et al., “Gender differences in healthy ranges for serum alanine aminotransferase levels in adolescence,” *PLoS One*, vol. 6, no. 6, article e21178, 2011.

[48] M. F. Feitosa, A. P. Reiner, M. K. Wojczynski et al., “Sex-influenced association of nonalcoholic fatty liver disease with coronary heart disease,” *Atherosclerosis*, vol. 227, no. 2, pp. 420–424, 2013.

[49] B. Buday, P. F. Pach, B. Literati-Nagy et al., “Sex influenced association of directly measured insulin sensitivity and serum transaminase levels: why alanine aminotransferase only predicts cardiovascular risk in men?,” *Cardiovascular Diabetology*, vol. 14, no. 1, article 55, 2015.

[50] U. Vespasiani-Gentilucci, P. Gallo, G. Piccinocchi et al., “Determinants of alanine aminotransferase levels in a large population from southern Italy: relationship between alanine aminotransferase and age,” *Digestive and Liver Disease*, vol. 46, no. 10, pp. 909–915, 2014.

[51] A. Javed, M. Jumean, M. H. Murad et al., “Diagnostic performance of body mass index to identify obesity as defined by body adiposity in children and adolescents: a systematic review and meta-analysis,” *Pediatric Obesity*, vol. 10, no. 3, pp. 234–244, 2015.

[52] A. P. Kennedy, J. L. Shea, and G. Sun, “Comparison of the classification of obesity by BMI vs. dual-energy X-ray absorptiometry in the Newfoundland population,” *Obesity*, vol. 17, no. 11, pp. 2094–2099, 2009.

[53] G. Banfi and P. Morelli, “Relation between body mass index and serum aminotransferases concentrations in professional athletes,” *The Journal of Sports Medicine and Physical Fitness*, vol. 48, pp. 197–200, 2008.

[54] H. Nyblom, U. Berggren, J. Balldin, and R. Olsson, “High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking,” *Alcohol and Alcoholism*, vol. 39, no. 4, pp. 336–339, 2004.